GT
AXDX icon

Glenmede Trust’s Accelerate Diagnostics AXDX Stock Holding History

Glenmede Trust’s Portfolio AXDX Stock Details AXDX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q3 		– Sell
-2,000
Closed -$14K – 1266
2023
Q2 		$14K Hold
2,000
– – ﹤0.01% 1243
2023
Q1 		$14K Buy
+2,000
New +$12K ﹤0.01% 1249

Other funds holding AXDX

GAM
Griffin Asset Management New York $949M AUM 24.98% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BC
Birchview Capital Burlington, Vermont $214M AUM 185.33% 1-Year Est. Return
OIM
Oracle Investment Management Greenwich, Connecticut $168M AUM 42.86% 1-Year Est. Return
Alyeska Investment Group
Alyeska Investment Group Chicago, Illinois $38.9B AUM 28.51% 1-Year Est. Return
CC
Cannell & Co New York $3.15B AUM 30.62% 1-Year Est. Return
CI
Chartist Inc Seal Beach, California $160M AUM 15.21% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
TWA
TCI Wealth Advisors Tucson, Arizona $2.31B AUM 26.52% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Glenmede Trust's AXDX Position: Q3 2023 in Review

Glenmede Trust sold out of Accelerate Diagnostics (AXDX) in Q3 2023, closing a stake of 2,000 shares — an estimated $14K sold.

Glenmede Trust first reported a position in AXDX in Q1 2023 and held it in 2 quarters. The position peaked at $14K in Q2 2023. 38 funds tracked by Wall St. Rank hold AXDX as of Q3 2023.

  • Glenmede Trust reported no remaining Accelerate Diagnostics position as of Q3 2023 after selling out during the quarter.
  • Glenmede Trust sold 2,000 Accelerate Diagnostics shares in Q3 2023, an estimated $14K.
  • Glenmede Trust first reported a position in Accelerate Diagnostics in Q1 2023 and held it in 2 quarters.
  • Glenmede Trust's Accelerate Diagnostics position peaked at $14K in Q2 2023.
  • 38 funds tracked by Wall St. Rank held Accelerate Diagnostics as of Q3 2023.

Based on Glenmede Trust's 13F filing for Q3 2023, filed 14 Nov 2023.